7 August 2008
PHARMAC reaffirms confidence in 9 week Herceptin treatment
After extensive investigation, PHARMAC has declined an application from the pharmaceutical company Roche to fund 12
month treatments with the breast cancer drug Herceptin, but will continue to fully fund the 9 week treatment.
The publicly funded 9 week treatment is a concurrent treatment (taken with chemotherapy) and is effective for women with
HER2-positive early breast cancer.
“A fresh review of the science and other information has failed to convince us that 12 month treatments offer any
additional benefits over the concurrent 9 week treatment,” said PHARMAC Chief Executive Matthew Brougham.
As with all its decisions, PHARMAC remains open to re-evaluating its position if new evidence emerges. This could
include results from the SOLD study, an international Herceptin clinical trial which PHARMAC is helping to fund, or
results from other clinical trials.
The Roche application failed on three grounds: clinical efficacy, cost effectiveness and patient safety (a greater risk
of cardiotoxicity and heart problems from longer exposure to Herceptin).
In order to have funded 12 month treatments, PHARMAC needed to be confident that:
12 month treatments would deliver health gains greater than could be achieved through a concurrent 9 week treatment;
and that
those benefits would be greater than would be achieved were the money spent on other medicines.
Herceptin for early breast cancer can be administered in two main ways, concurrently with chemotherapy or sequentially
after chemotherapy. The Pharmacology and Therapeutics Advisory Committee (“PTAC”), the independent clinical experts that
advise PHARMAC, recommended against either 12 month treatment being funded. PHARMAC’s decision is consistent with that
advice.
The SOLD study comparing 12 months to 9 weeks, which has been supported by oncologists and sanctioned by approval
bodies, would not have been permitted to proceed if the optimal use of Herceptin was already known. Roche itself
acknowledged in its submission to PHARMAC that “the issues of optimal duration and sequence of Herceptin treatment
remain unanswered at this time”.
PHARMAC also gave careful consideration to an updated commercial offer from Roche.
“PHARMAC has commercial-in-confidence arrangements with pharmaceutical suppliers that we don’t want to jeopardise. But I
think it is fair and important to put on the public record that Roche’s revised offer has been significantly over-hyped
in the media.
This decision, however, was not driven by the price of the 12 month treatments. It was based on a lack of confidence
that the expenditure – whatever the exact level – would deliver any additional health gains,” said Matthew Brougham.
“It is disappointing therefore that some commentators continue to assert that Herceptin is a ‘wonder drug’ and that a 12
month treatment is the ‘gold standard’. Such claims are exaggerated and misleading, and ultimately do a disservice to
affected women and their families contemplating their treatment options.”
Herceptin is a beneficial add-on treatment, but the extent of those benefits must be kept in perspective. In the
clinical trials, which have reported benefits over a short number of years, 74 to 88 out of every 100 patients who did
not get Herceptin have remained disease free. Looking across all trials, Herceptin (9 weeks or 12 months) had a small
but significant benefit, with between 1 and 13 patients out of every 100 treated with Herceptin getting that extra
benefit.
Matthew Brougham said that this had been a difficult decision, given the high profile of Herceptin and extensive
advocacy for the 12 month treatment.
“It is only natural to feel empathy for sufferers of breast cancer and other serious illnesses. PHARMAC must though look
carefully at all funding applications and all relevant evidence – not just agree to what pharmaceutical companies or
patient interest groups want. New Zealand’s pharmaceutical budget is not bottomless and it is our duty to ensure that it
is well-spent. Even if more funding is provided for medicines, we would go through our normal careful process of
deciding how best to spend that money to achieve the best health outcomes. Most New Zealanders would expect we do this
to be fair to all.”
PHARMAC is aware of the very high level of public interest in this matter and is making available to the public as much
detail about its decision as possible.
PHARMAC conducted a rigorous assessment process and undertook a full consultation; extending the usual response period
by one month, seeking new advice from its expert committees and revising its cost-utility analysis.
“About 300 submissions were received, and we are grateful for the high level of engagement. PHARMAC has published a
submission summary, underscoring the careful consideration given to the information and perspectives that were shared.
Significant other material is on our website. The submissions and advice to the PHARMAC Board can also be provided on
request. We want people to have access to the full range of considerations that guided our thinking.”
ENDS
Herceptin
Questions and Answers
7 August 2008
Is Herceptin funded in New Zealand?
Yes. New Zealanders continue to have fully funded access to an effective and full course of Herceptin treatment for
HER2-positive early breast cancer – concurrent 9 week treatment with a taxane drug (docetaxel or paclitaxel).
About 350-400 New Zealand women are diagnosed with HER2-positive breast cancer each year, and these women are all
eligible for this treatment.
Why is a concurrent 9 week course funded?
Herceptin for early breast cancer can be administered in two main ways: at the same time as (concurrently) or after
(sequentially) other chemotherapy treatment.
There is a lot of debate internationally about the best way to administer Herceptin, but the current evidence shows that
concurrent therapy probably provides a better result than sequential.
The 9 week course of Herceptin, concurrent with a taxane (chemotherapy), has been demonstrated to delay the recurrence
of breast cancer with similar results to other ways of using Herceptin. A shorter course means less exposure to the
treatment and perhaps reduced side effects, such as heart failure, than the longer duration treatments.
Is the funded 9 week treatment effective?
Yes. The FinHer trial demonstrated that 9 week Herceptin treatment delayed breast cancer returning in women with
HER2-positive early breast cancer. FinHer, although smaller than other trials, is a scientifically robust study and its
key results were statistically significant. The benefit of the 9 week treatment is comparable to the 12 month treatments
for disease free survival.
Why not fund the 12 month treatments?
New Zealanders have access to a fully funded, effective Herceptin treatment for early HER2-positive breast cancer – the
9 week treatment. A fresh review of the science and other information has failed to convince us that the 12 month
treatment offers any additional benefits over the 9 week treatment. To justify the additional expense, we first would
need to be confident that 12 months treatment offered additional health outcomes, and we don’t have that confidence.
The only way to tell for sure whether the additional cost (and risk) of extending treatment duration is worth it, is to
conduct a head-to-head study. That is why we are financially supporting a study, the SOLD study.
PHARMAC sought advice on this issue from its expert clinical advisors, the Pharmacology and Therapeutics Advisory
Committee (“PTAC”), PHARMAC’s decision is consistent with that advice. Relevant PTAC Minutes are available on PHARMAC’s
website.
If the comparison of long vs short is so important, why has Roche not looked at it?
From PHARMAC’s perspective, pharmaceutical suppliers should – as the companies that profit from selling medicines – do
all they can to test different treatment regimens, including shorter treatments. It is not clear why 12 months became
Roche’s preferred treatment length, and not 11 months, 6 or even 9 weeks. The HERA study, funded by Roche, is looking at
even longer duration of treatment (2 years).
Understanding the optimal treatment duration is often an issue for PHARMAC when funding medicines. PHARMAC must do all
it can to consider all evidence before making decisions on what treatment approaches are best.
Why is NZ currently funding a different treatment regimen to other countries?
PHARMAC’s role is to make funding decisions that are in the best interests of New Zealanders. This means making our own
decisions independently of other countries.
In some countries, the 9 week treatment could not be considered for funding due to rules around their registration and
funding processes, which means that they are not able to take into account all of the evidence.
Concurrent 9 week treatment with Herceptin is available as a treatment choice in some other countries, and international
debate about the need for longer duration treatment continues – underscoring the uncertainty PHARMAC has found.
PHARMAC is helping to fund an international clinical trial (SOLD) to assess whether there are any additional treatment
benefits from adding longer-duration treatment to a concurrent 9 week treatment regimen.
Didn’t PHARMAC decide to not fund 12 months treatment long ago?
A group of eight women sought judicial review of PHARMAC’s earlier decision-making in the High Court. In its decision,
released in April 2008, the Court rejected all but one of the 28 points raised by the plaintiffs. The Court set aside
PHARMAC’s July 2006 decision to decline Roche’s application for funding 12 months treatments with Herceptin for
HER2-positive early breast cancer, and directed PHARMAC to make a new decision following consultation.
What was the process followed?
PHARMAC exceeded the requirements imposed on it by the High Court for this process. PHARMAC sought public feedback on a
new proposal to decline funding for the 12 months treatments. In addition, PHARMAC:
met face to face with a number of interested groups – including breast cancer patients and oncologists;
considered a new bundled commercial offer from Roche, the supplier of Herceptin;
sought advice from PTAC, and PTAC’s cancer treatments sub-committee (CaTSoP) on new clinical information; and
updated its budget impact and cost-utility analyses of Herceptin.
What did the new information or advice show?
More than 300 consultation responses were received. These came from individuals, groups representing patients,
oncologists and oncology groups, public health medicine specialists and District Health Boards. Submissions were
received from New Zealand and overseas. A summary of submissions, issues raised, and PHARMAC’s responses, are available
at www.pharmac.govt.nz.
PTAC and the cancer treatments sub-committee reviewed new clinical information from Herceptin studies N9831/B31 and a
new study PACS04. PTAC members commented that the emerging data from studies seem to indicate that sequential 12 months
treatment with trastuzumab (the treatment approved by Medsafe for New Zealand) may be a less effective use of the agent
in treating HER2 positive early breast cancer patients. PTAC recommended that funding of 12 months treatments
(sequential and concurrent) should be declined. PTAC’s view was that no new information had been presented that
demonstrated any additional health benefit over the currently funded concurrent 9 week treatment regimen. PTAC
recommended that current funding for the 9 week treatment be continued.
The new commercial offer from Roche was also carefully considered.
Did PHARMAC consider all clinical evidence?
Yes, PHARMAC looked at all available evidence, both published and unpublished. PHARMAC is concerned about the selective
publication of evidence around Herceptin (publication bias). These issues have been reported on in The Lancet medical
journal, linked on PHARMAC’s website. A full summary of the currently available clinical evidence is also available on
the website.
What happens now?
The full and effective concurrent 9 week Herceptin treatment remains fully funded for all eligible New Zealanders as a
complete treatment regimen. PHARMAC remains open to considering new information if and when it becomes available.
ENDS